Alkermes plc ALKS · SEC Filings

2.1K

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercializati...

Price46.17

Market Cap7.75 B

Float155.45 M

CountryIE

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 28, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 28, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 29, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Alkermes plc Reports Third Quarter 2026 Financial Results

Nov 3, 2026

8-K

Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHD

Sep 21, 2026

8-K

Alkermes plc Appoints Anne C. Whitaker to Board of Directors

Sep 16, 2026

8-K

Alkermes plc Amends Credit Agreement to Reduce Interest Rates

Aug 12, 2026

8-K/A

Blair C. Jackson Appointed CEO and President, Receives New Compensation Package and Board Position Effective August 2026

Aug 3, 2026

8-K

Alkermes Reports Q2 2026 Financial Results and Announces CEO Transition

Jul 28, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 13, 2014

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Mar 8, 2012

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Mar 7, 2012

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Aug 5, 2011

425

Form 425 - Prospectuses and communications, business combinations

Jul 27, 2011

425

Form 425 - Prospectuses and communications, business combinations

Jul 27, 2011

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 28, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 29, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 24, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 26, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 27, 2022

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 28, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 13, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 6, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 6, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 12, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 7, 2025

Ownerships

TYPE

HEADLINE

FILED AT

4

Gaffin David Joseph (Reporting)

Nov 3, 2026

144

Form 144 - Report of proposed sale of securities

Nov 3, 2026

4

Reed Joshua (Reporting)

Oct 9, 2026

4

Whitaker Anne Clem (Reporting)

Oct 9, 2026

4

Gaffin David Joseph (Reporting)

Oct 2, 2026

144

Form 144 - Report of proposed sale of securities

Oct 2, 2026

Other

TYPE

HEADLINE

FILED AT

CORRESP

Form CORRESP - Correspondence

May 19, 2023

LETTER

Form UPLOAD - SEC-generated letter

May 19, 2023

LETTER

Form UPLOAD - SEC-generated letter

May 16, 2023

CT ORDER

Form CT ORDER - Confidential treatment order

May 19, 2020

CT ORDER

Form CT ORDER - Confidential treatment order

Dec 4, 2019

CT ORDER

Form CT ORDER - Confidential treatment order

Mar 14, 2019